Robert M. Kotin
Direktor/Vorstandsmitglied bei Carbon Biosciences, Inc.
Profil
Robert M.
Kotin was the founder of Generation Bio Co. founded in 2016, where he held the title of Discovery Head.
Currently, he is a Director at Carbon Biosciences, Inc. Dr. Kotin's former positions include Head-AAV Gene Therapy Program at Genetic Therapy, Inc., Senior Research Scientist at Lederle Laboratories, and Vice President-Virology & Gene Therapy at Voyager Therapeutics, Inc. He was also a Senior Investigator & Laboratory Chief at the National Heart, Lung & Blood Institute.
Dr. Kotin holds a doctorate degree from the University of Medicine & Dentistry of New Jersey and Rutgers State University of New Jersey.
He also holds an undergraduate degree from the University of California, Santa Cruz.
Aktive Positionen von Robert M. Kotin
| Unternehmen | Position | Beginn |
|---|---|---|
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Robert M. Kotin
| Unternehmen | Position | Ende |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2016 |
| Weill Cornell Medical College | Corporate Officer/Principal | 01.01.1990 |
| GENERATION BIO CO. | Gründer | - |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Lederle Laboratories
 Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Corporate Officer/Principal | - |
Ausbildung von Robert M. Kotin
| University of California, Santa Cruz | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| GENERATION BIO CO. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| National Heart, Lung & Blood Institute | Government |
Lederle Laboratories
Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Commercial Services |
Genetic Therapy, Inc.
Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
